Breaking Merger News: Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and TenX Keane Join Forces

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Needs to be #1 on Today's Watchlist

Market Crux Exclusive: Citius Pharmaceuticals, Inc. (Nasdaq: CTXR)  Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Needs to be #1 on  Today’s Watchlist! Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Comes Backed with  Several Potential Catalysts Including: Recent Market Recognition: Shares Up 93% In Less Than A Month,  From $.48 On July 3 To $.93! Bullish Momentum: Shares Surpassed All Major Moving Averages,  Per Barchart's Analysis! Analyst Coverage: EF Hutton Targets $6.00, Suggesting a 561%  Potential Upside! Upcoming FDA Decision On LYMPHIR™: FDA Decision Expected on  August 13, 2024! IPO For LYMPHIR™: Planned IPO This Summer Could Boost  Funding and Visibility! Positive Phase 3 Results For Mino-Lok®: Positive Topline Results  Announced in May 2024! Orphan Designation: LYMPHIR™ Received Orphan Designation,  Potentially 12 Years Exclusivity! August 5, 2024 Dear Reader, Despite all the red you may see in the market today, do not miss this chance to pull up Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) right now! Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has just announced that TenX Keane shareholders have approved their merger with Citius Oncology, Inc.! This transformative deal will see Citius Pharmaceuticals receiving 65.6M shares of the newly renamed Citius Oncology, Inc., maintaining approximately 90% majority control post-merger.  The combined entity is expected to trade on Nasdaq as Citius Oncology, Inc. This merger is set to propel the commercialization of LYMPHIR, if approved, and open doors to further oncology ventures.  With unanimous backing from the Boards of both companies, the merger is on track to be finalized in the coming weeks, setting the stage for significant growth. Don’t miss out on this critical update!  Pull up Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) right now and see the full announcement here: See the full announcement here. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) appears to be gaining significant market recognition as it moved approximately 93% in less than a month, coming off its 52-week low of $.48 on July 3, 2024, reaching $.93 just this past Friday.  Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) appears to be gaining significant market recognition, moving approximately 93% in less than a month from $.48 on July 3, 2024, to $.93 this past Friday. This bullish momentum has pushed (CTXR) past all major moving averages, according to Barchart's technical analysis tool: 5-Day MA: $.9266 20-Day MA: $.8409 50-Day MA: $.7112 100-Day MA: $.7398 200-Day MA: $.7440 Year-to-Date MA: $.7337 Adding to the excitement, EF Hutton, a prominent Wall Street firm, has initiated coverage of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) with a target of $6.00, suggesting a potential upside of approximately 561% from Friday’s $.906 close. With significant upcoming events like an FDA decision and a planned IPO, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is on the cusp of transformative growth. Keep reading to discover why Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) needs to be at the top of your watchlist tomorrow. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company committed to developing and commercializing first-in-class critical care products.  With a diversified pipeline of late-stage product candidates, Citius is poised for significant growth and transformation in the biopharmaceutical industry.  Analyst Coverage and Potential Upside EF Hutton's analyst Jason Kolbert has expressed a bullish outlook on Citius Pharmaceuticals, primarily due to the promising late-stage therapeutics Mino-Lok and LYMPHIR. The potential initial public offering (IPO) for LYMPHIR this summer and an early August Prescription User Fee Act (PDUFA) date are seen as significant catalysts for the company.  This positive coverage underscores the transformative potential of Citius's pipeline and strategic initiatives. Recent Developments and Near-Term Milestones Citius Pharmaceuticals has made substantial progress in advancing its late-stage product candidates and achieving key operational milestones.  Here are some notable developments: Mino-Lok®: In May 2024, Citius announced positive topline results from the Phase 3 study of Mino-Lok®, an antibiotic lock solution designed to salvage catheters in patients with bloodstream infections. The study met both primary and secondary endpoints with statistical significance. Next steps include preparing a submission to the U.S. FDAand scheduling a Type B meeting. LYMPHIR™: The Biologics License Application (BLA) for LYMPHIR™, a novel IL-2R immunotherapy for treating cutaneous T-cell lymphoma (CTCL), is currently under FDA review, with August 13, 2024, set as the PDUFA target action date. If approved, LYMPHIR™ could potentially receive 12 years of exclusivity as a new biologic. Citius is preparing for the near-term commercialization of LYMPHIR™. LYMPHIR™ has received orphan designation for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Ongoing Phase 1 studies are exploring additional indications for LYMPHIR™. Halo-Lido: Citius completed enrollment in its Phase 2b trial of Halo-Lido (CITI-002), a topical formulation for relieving hemorrhoid symptoms. Positive data from the trial showed a meaningful reduction in symptom severity. The company held an end-of-Phase 2b meeting with the FDA to discuss the next phase of development for Halo-Lido. Operational Achievements Citius Pharmaceuticals has also strengthened its fiscal position and operational capabilities: Capital Structure: In April 2024, Citius completed a $15M registered direct offering, extending the company's ca-sh runway and supporting future growth initiatives. Oncology Spin-Off: Citius plans to form Citius Oncology, Inc., a standalone publicly traded company with LYMPHIR™ as its primary asset. This transaction is pending review by the U.S. Securities and Exchange Commission (SEC) and approval by TenX Keane Acquisition (Nasdaq: TENK) shareholders. National Sales Director: Citius has on-boarded a National Sales Director to recruit and lead the sales organization in preparation for the anticipated launch of LYMPHIR™. Leadership Perspective Leonard Mazur, Chairman and CEO of Citius, emphasized the company's strategic vision and operational achievements:  "Our solid execution since the beginning of the year sets us up for potentially transformative catalysts in the coming months. Mino-Lok's strong Phase 3 topline results support its potential to become part of the standard of care for treating catheter-related bloodstream infections. For LYMPHIR™, the FDA is currently reviewing our Biologics License Application, with an expected decision on August 13th. We are preparing for near-term commercialization of LYMPHIR if approved. These near-term catalysts should enable the company to optimize its current ca-sh runway, future ca-sh needs, as well as create potential non-dilutive ca-sh opps." Mazur added, "Our primary purpose and mission for these late-stage assets is to provide best-in-class, highly effective treatment options for patients and caregivers. Ultimately, we believe our achievements and milestones offer powerful levers for value creation." Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is at a pivotal point in its journey, with significant near-term milestones and transformative catalysts on the horizon.  The company's innovative late-stage product candidates, Mino-Lok and LYMPHIR, are poised to address critical unmet medical needs and offer substantial market potential.  With a strong fiscal foundation and strategic operational initiatives, Citius is well-positioned for sustained growth and value creation. Industry stakeholders should keep a close eye on Citius Pharmaceuticals as it continues to advance its pipeline and achieve key milestones in 2024. 7 reasons to immediately add Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) to the top of your watchlist. 1. Recent Market Recognition: Citius Pharmaceuticals has seen its shares move approximately 93% in less than a month, moving from $.48 on July 3, 2024, to $.93 last Friday. 2. Bullish Momentum: Shares of Citius Pharmaceuticals have pushed it past all major moving averages, according to Barchart's technical analysis tool, indicating strong technical momentum. 3. Analyst Coverage: EF Hutton, a leading Wall Street firm, has initiated coverage with a target price of $6.00, suggesting a significant 561% potential upside from the recent closing price. 4. Upcoming FDA Decision on LYMPHIR™: An FDA decision on the Biologics License Application (BLA) for LYMPHIR™, an IL-2R immunotherapy, is expected on August 13, 2024. This could be a pivotal moment for the company. 5. IPO for LYMPHIR™: A planned IPO for LYMPHIR™ this summer could provide additional funding and market visibility for Citius Pharmaceuticals. 6. Positive Phase 3 Results for Mino-Lok®: In May 2024, Citius announced positive topline results from the Phase 3 study of Mino-Lok®, meeting both primary and secondary endpoints with statistical significance. 7. Orphan Designation: LYMPHIR™ has received orphan designation for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), potentially providing 12 years of market exclusivity if approved. Keep an eye on Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) as it has attracted considerable market recognition with its approximate 93% move in less than a month. Shares of (CTXR) moved from $.48 on July 3, 2024, to $.93 last Friday, breaking past all major moving averages according to Barchart's technical analysis tool. EF Hutton, a prominent Wall Street firm, has initiated coverage with a target of $6.00, indicating a potential upside of approximately 561% from Friday’s close. The impending FDA decision on the Biologics License Application (BLA) for LYMPHIR™, expected on August 13, 2024, could be a crucial milestone for the company. Additionally, the planned IPO for LYMPHIR™ this summer could bring vital funding and greater market visibility. Citius Pharmaceuticals has announced positive Phase 3 results for Mino-Lok® and obtained orphan designation for LYMPHIR™, potentially offering 12 years of market exclusivity if approved.  Given these significant developments, you should immediately start your research on Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and make sure its #1 on your watchlist this morning. Pull up Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) right now and have it ready for this morning. Do not miss this chance to pull up (CTXR) right now. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux (MarketCrux . com) is owned by Headline Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. MarketCrux full disclosure is to be read and fully understood before using MarketCrux website, or joining MarketCrux's email or text list. By viewing MarketCrux website and/or reading MarketCrux email or text newsletter you are agreeing to MarketCrux full disclosure which can be read at marketcrux.com/disclaimer Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 08/04/2024 and ending on 08/05/2024 to publicly disseminate information about (CTXR:US) via digital communications. Headline Media LLC has been paid five thousand USD and owns zero shares of (CTXR:US). In the last [93] days we have been paid a total of five thousand USD. We own zero shares of (CTXR:US). Headline Media LLC has long standing paid publicity agreements for (CTXR:US). Please contact us for more information about amounts paid for publicly disseminating information in previous periods. Please see important disclosure information here: https://marketcrux.com/ctxr-disclosure-1064/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice